azithromycinWhat was measured
Measured, with no finding
304 endpoints
Show what was measuredHide what was measured
all-cause mortality, Bayesian pooled relative risk
no effect
pooled RR for mortality of 0.93 (95% CI 0.72–1.14, n = 17 studies)
PMID 32860962 · one of two readings recorded this
all-cause mortality, Bayesian pooled relative risk
no effect
pooled RR for mortality of 1.32 (95% CI 0.97–1.68, n = 7 studies)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk, observational studies with moderate risk of bias
no effect
RRmoderate bias = 1.03 (95% CI 0.91–1.17
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk, sensitivity analysis including critical-risk studies
no effect
the global RR was marginally not significant 0.80 (95% CI 0.65–1.00)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk
no effect
All studies | 17 | 0.83 (0.65–1.06) | -4.4% (–9% to +1.5%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk
increases
All studies | 7 | 1.27 (1.04–1.54) | +7% (+1% to +14%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk
no effect
Non-randomized studies | 14 | 0.79 (0.60–1.04) | -5.5% (–10% to +1%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk
no effect
Randomized studies | 3 | 1.09 (0.97–1.24) | +2.3% (–0.8% to +6.2%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk
increases
Non-randomized studies | 6 | 1.29 (1.06–1.58) | +7.5% (+1.6% to +15%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, pooled relative risk
no effect
Randomized studies | 1 | 0.64 (0.18–2.24) | -9% (–21% to +32%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, risk difference
no effect
All studies | 17 | 0.83 (0.65–1.06) | -4.4% (–9% to +1.5%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, risk difference
increases
All studies | 7 | 1.27 (1.04–1.54) | +7% (+1% to +14%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, risk difference
no effect
Non-randomized studies | 14 | 0.79 (0.60–1.04) | -5.5% (–10% to +1%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, risk difference
no effect
Randomized studies | 3 | 1.09 (0.97–1.24) | +2.3% (–0.8% to +6.2%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, risk difference
increases
Non-randomized studies | 6 | 1.29 (1.06–1.58) | +7.5% (+1.6% to +15%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, risk difference
no effect
Randomized studies | 1 | 0.64 (0.18–2.24) | -9% (–21% to +32%)
PMID 32860962 · one of two readings recorded this
all-cause mortality, subgroup difference randomized vs non-randomized
p = 0.03
(Pheterogeneity between = 0.03)
PMID 32860962 · one of two readings recorded this
all-cause mortality, subgroup difference randomized vs non-randomized
no effect, p = 0.28
(Pheterogeneity between = 0.28)
PMID 32860962 · one of two readings recorded this
COVID-19 mortality, pooled relative risk, hydroxychloroquine with azithromycin versus standard of care (all-cause mortality per Table 1)
increases, RR 1.27 (95% CI 1.04-1.54, n = 7 studies), n = 7
Not recorded as a finding: the intervention held more than the compound
After exclusion of studies with critical bias, the pooled RR for COVID-19 mortality was 1.27 (95% CI 1.04–1.54, n = 7), indicating an increased mortality linked to the use of hydroxychloroquine with azithromycin.
PMID 32860962 · one of two readings recorded this
COVID-19 mortality, pooled relative risk, hydroxychloroquine with azithromycin versus standard of care (studies at critical risk of bias excluded)
increases, pooled RR 1.27 (95% CI 1.04-1.54, n = 7), n = 7
Not recorded as a finding: the intervention held more than the compound
After exclusion of studies with critical bias, the pooled RR for COVID-19 mortality was 1.27 (95% CI 1.04–1.54, n = 7), indicating an increased mortality linked to the use of hydroxychloroquine with azithromycin.
PMID 32860962 · one of two readings recorded this
deaths, hydroxychloroquine group
with 3152 deaths, 1063 deaths and 2857 deaths, respectively
PMID 32860962 · one of two readings recorded this
deaths, hydroxychloroquine with azithromycin group
with 3152 deaths, 1063 deaths and 2857 deaths, respectively
PMID 32860962 · one of two readings recorded this
deaths, standard of care group
with 3152 deaths, 1063 deaths and 2857 deaths, respectively
PMID 32860962 · one of two readings recorded this
publication bias, Begg's test
no effect, p = 0.13
Begg's test (p 0.13)
PMID 32860962 · one of two readings recorded this
publication bias, Begg's test
no effect, p = 0.65
Begg's test (p 0.65)
PMID 32860962 · one of two readings recorded this
publication bias, Egger's test
no effect, p = 0.68
Egger's test (p 0.68)
PMID 32860962 · one of two readings recorded this
publication bias, Egger's test
no effect, p = 0.7
Egger's test (p 0.70)
PMID 32860962 · one of two readings recorded this
prevalence of peak QTc >=500 ms
was 9% (95% confidence interval [95%CI], 3%-18%)
PMID 33772933 · one of two readings recorded this
prevalence of peak QTc >=500 ms
8% (95%CI, 3%-14%)
PMID 33772933 · one of two readings recorded this
QTc prolongation (peak QTc >=500 ms, peak QTc change >=60 ms) in COVID-19 patients, pooled risk ratio versus no treatment
increases, RR 3.28; 95%CI 1.16-9.30 for hydroxychloroquine + azithromycin
Not recorded as a finding: the intervention held more than the compound
Likewise, the use of hydroxychloroquine (risk ratio [RR], 2.68; 95%CI, 1.56-4.60) and hydroxychloroquine + azithromycin (RR, 3.28; 95%CI, 1.16-9.30) was associated with an increased risk of QTc prolongation compared to no treatment.
PMID 33772933 · one of two readings recorded this
risk of QTc prolongation in COVID-19 patients (peak QTc 500 ms or more, peak QTc change 60 ms or more), pooled risk ratio versus no treatment; abstract only
increases, hydroxychloroquine + azithromycin RR, 3.28; 95%CI, 1.16-9.30
Not recorded as a finding: the intervention held more than the compound
Likewise, the use of hydroxychloroquine (risk ratio [RR], 2.68; 95%CI, 1.56-4.60) and hydroxychloroquine + azithromycin (RR, 3.28; 95%CI, 1.16-9.30) was associated with an increased risk of QTc prolongation compared to no treatment.
PMID 33772933 · one of two readings recorded this
risk of QTc prolongation versus no treatment
increases
hydroxychloroquine + azithromycin (RR, 3.28; 95%CI, 1.16-9.30)
PMID 33772933 · one of two readings recorded this
risk of QTc prolongation versus no treatment
increases
the use of hydroxychloroquine (risk ratio [RR], 2.68; 95%CI, 1.56-4.60)
PMID 33772933 · one of two readings recorded this
length of stay, difference in medians
no effect, delta = 1.11, 95% CI -2.08 to 4.31, p = 0.49, p = 0.49
Not recorded as a finding: setting and unit not stated in the abstract, so cannot be mapped onto hospital-length-of-stay with its setting requirement
The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49).
PMID 34077600 · one of two readings recorded this
length of stay, pooled difference in medians
no effect, Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49, p = 0.49
Not recorded as a finding: abstract does not say hospital or ICU stay, so hospital-length-of-stay setting and unit are unstated
The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49).
PMID 34077600 · one of two readings recorded this
length of stay
no effect, p = 0.49
length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49)
PMID 34077600 · one of two readings recorded this
mortality (deaths)
There were 657/3100 (21.2%) and 1244/5654 (22%) deaths among patients randomized to AZM and standard of care, respectively
PMID 34077600 · one of two readings recorded this
mortality (deaths)
There were 657/3100 (21.2%) and 1244/5654 (22%) deaths among patients randomized to AZM and standard of care, respectively
PMID 34077600 · one of two readings recorded this
mortality
no effect, p = 0.317
The use of AZM was not associated with mortality in Covid-19 patients (OR = 0.96, 95% CI 0.88-1.05, p = 0.317 based on the random-effect meta-analysis)
PMID 34077600 · one of two readings recorded this
need for invasive mechanical ventilation, pooled OR
no effect, OR = 0.96, 95% CI 0.49-1.87, p = 0.85, p = 0.85
Not recorded as a finding: proportion needing ventilation is not the node's duration of mechanical ventilation
The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49).
PMID 34077600 · both readings recorded this
need for invasive mechanical ventilation
no effect, p = 0.85
The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85)
PMID 34077600 · one of two readings recorded this
TNF-α
decreases, p = 0.00001
TNF-α (MD = -9.09, 95% CI[-10.91, -7.27], P<0.00001)
PMID 34255785 · one of two readings recorded this
IL-6
decreases, p = 0.0001
For IL-6 (MD = -8.35, 95% CI[-12.31, -4.4], P<0.0001)
PMID 34255785 · one of two readings recorded this
IL-8
decreases, p = 0.00001
IL-8 (MD = -4.49, 95% CI[-5.12, -3.87], P<0.00001)
PMID 34255785 · one of two readings recorded this
adverse rate (incidence)
decreases, p = 0.00001
(MD = 0.44, 95% CI[0.35, 0.56], P<0.00001)
PMID 34255785 · one of two readings recorded this
adverse rate (incidence)
decreases, p = 0.00001
(MD = 0.36, 95% CI [0.27, 0.47], P < 0.00001)
PMID 34255785 · one of two readings recorded this
adverse rate (incidence)
no effect, p = 0.59
(MD = 0.88, 95% CI[0.54, 1.41], P = 0.59)
PMID 34255785 · one of two readings recorded this
adverse rate, subgroup heterogeneity by mode of administration
p = 0.001
the mode of administration (P = 0.001, I2 = 90.3%)
PMID 34255785 · one of two readings recorded this
average hospitalization time
decreases, p = 0.00001
(MD = -4.19, 95% CI[-5.03, -3.34], P<0.00001)
PMID 34255785 · one of two readings recorded this
CD3+ T-lymphocytes
increases, p = 0.00001
For CD3+ T-lymphocytes (MD = 6.68, 95% CI[5.29, 8.06], P<0.00001)
PMID 34255785 · one of two readings recorded this
CD4+/CD8+ ratio
increases, p = 0.0002
CD4/CD8 (MD = 0.31, 95% CI[0.14, 0.47], P = 0.0002)
PMID 34255785 · one of two readings recorded this
CD4+ T-lymphocytes
increases, p = 0.00001
CD4+ T-lymphocytes (MD = 4.78, 95% CI[3.76, 5.81], P<0.00001)
PMID 34255785 · one of two readings recorded this
CD8+ T-lymphocytes
decreases, p = 0.00001
CD8+ T-lymphocytes (MD = -4.52, 95% CI[-5.28, -3.77], P<0.00001)
PMID 34255785 · one of two readings recorded this
disappearance time of cough, subgroup analysis by age
p = 0.0002
age (P = 0.0002, I2 = 93%)
PMID 34255785 · one of two readings recorded this
disappearance time of cough, subgroup analysis by course of disease
p = 0.0001
course of disease (P = 0.0001, I2 = 93.2)
PMID 34255785 · one of two readings recorded this
disappearance time of cough, subgroup analysis by drug delivery way
p = 0.02
drug delivery way (P = 0.02, I2 = 82.3%)
PMID 34255785 · one of two readings recorded this
disappearance time of cough
decreases, p = 0.00001
(MD = -2.95, 95% CI [- 3.55, -2.34], P < 0.00001)
PMID 34255785 · one of two readings recorded this
disappearance time of fever, sensitivity analysis excluding one study
decreases
(MD = -1.51, 95% CI [- 1.74, -1.28])
PMID 34255785 · one of two readings recorded this
disappearance time of fever
decreases, p = 0.00001
(MD = -1.72, 95% CI[-2.47, -0.97], P<0.00001)
PMID 34255785 · one of two readings recorded this
disappearance time of pulmonary rales, sensitivity analysis excluding Lu 2017
decreases
(MD = -1.95, 95% CI[-2.47, -1.44])
PMID 34255785 · one of two readings recorded this
disappearance time of pulmonary rales, subgroup analysis by age
p = 0.0004
age (P = 0.0004, I2 = 92.1%)
PMID 34255785 · one of two readings recorded this
disappearance time of pulmonary rales, subgroup analysis by course of disease
p = 0.16
course of disease (P = 0.16, I2 = 49.7%)
PMID 34255785 · one of two readings recorded this
disappearance time of pulmonary rales, subgroup analysis by drug delivery way
p = 0.00004
drug delivery way (P = 0.00004, I2 = 92.1%)
PMID 34255785 · one of two readings recorded this
disappearance time of pulmonary rales
decreases, p = 0.00001
(MD = -2.13, 95% CI[-2.88, -1.38], P<0.00001)
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of cough
decreases, p = 0.0007
Age | -0.6432 | 0.0007 | [-1.0165, -0.2698] ***
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of cough
decreases, p = 0.0004
Course of disease | -0.331 | 0.0004 | [-0.5148, -0.1473] ***
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of cough
no effect, p = 0.0892
Course of treatment | 0.0464 | 0.0892 | [-0.0071, 0.1000]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of cough
no effect, p = 0.4229
Dosage form | 0.609 | 0.4229 | [-2.0987, 0.8806]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of cough
increases, p = 0.0477
Drug delivery way | 1.1272 | 0.0477 | [0.0112, 2.2432] *
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of cough
no effect, p = 0.0758
Disappearance time of cough | Sample size | 0.0113 | 0.0758 | [-0.0012, 0.0238]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of fever
no effect, p = 0.3684
Age | -0.2208 | 0.3684 | [-0.7018, 0.2603]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of fever
no effect, p = 0.7877
Course of disease | -0.0406 | 0.7877 | [-0.3360, 0.2548]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of fever
no effect, p = 0.3308
Course of treatment | 0.0261 | 0.3308 | [-0.0265, 0.0787]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of fever
no effect, p = 0.6281
Dosage form | -0.5253 | 0.6281 | [-2.6512, 1.6005]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of fever
no effect, p = 0.5857
Drug delivery way | -0.5795 | 0.5857 | [-2.6637, 1.5046]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of fever
no effect, p = 0.5055
Disappearance time of fever | Sample size | -0.0051 | 0.5055 | [-0.0202, 0.0100]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of pulmonary rales
no effect, p = 0.5357
Age | -0.0765 | 0.5357 | [-0.3184, 0.1655]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of pulmonary rales
increases, p = 0.0098
Course of disease | 0.5018 | 0.0098 | [0.1212, 0.8824] **
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of pulmonary rales
no effect, p = 0.1061
Course of treatment | -0.074 | 0.1061 | [-0.1639, 0.0158]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of pulmonary rales
no effect, p = 0.0824
Dosage form | 1.9003 | 0.0824 | [-0.2443, 4.0449]
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of pulmonary rales
decreases, p = 0.0119
Drug delivery way | -1.0331 | 0.0119 | [-1.8384, -0.2278] *
PMID 34255785 · one of two readings recorded this
meta-regression of disappearance time of pulmonary rales
decreases, p = 0.0001
Disappearance time of pulmonary rale | Sample size | -0.026 | <0.0001 | [-0.0356, -0.0165] ***
PMID 34255785 · one of two readings recorded this
meta-regression of response rate
no effect, p = 0.4422
Age | -0.0071 | 0.4422 | [-0.0251, 0.0109]
PMID 34255785 · one of two readings recorded this
meta-regression of response rate
decreases, p = 0.0051
Course of disease | -0.0147 | 0.0051 | [-0.0249, -0.0044] **
PMID 34255785 · one of two readings recorded this
meta-regression of response rate
no effect, p = 0.1414
Course of treatment | -0.0028 | 0.1414 | [-0.0065, 0.0009]
PMID 34255785 · one of two readings recorded this
meta-regression of response rate
no effect, p = 0.1388
Dosage form | -0.077 | 0.1388 | [-0.1790, 0.0249]
PMID 34255785 · one of two readings recorded this
meta-regression of response rate
no effect, p = 0.4143
Drug delivery way | 0.0369 | 0.4143 | [-0.0517, 0.1255]
PMID 34255785 · one of two readings recorded this
meta-regression of response rate
no effect, p = 0.2071
Response rate | Sample size | -0.0004 | 0.2071 | [-0.001,0.0002]
PMID 34255785 · one of two readings recorded this
response rate, SHL + azithromycin vs azithromycin alone
increases, p = 0.00001
(RR = 1.14, 95% CI[1.11, 1.18], P<0.00001)
PMID 34255785 · one of two readings recorded this
response rate, subgroup analysis by course of disease
no effect, p = 0.39
the course of the disease was not the source of heterogeneity (P = 0.39, I2 = 0%)
PMID 34255785 · one of two readings recorded this
response rate
n = 1442
1374 of 1442 patients (95.28%) receiving the SHL combined with azithromycin and 1186 of 1442 patients (82.25%) receiving azithromycin alone
PMID 34255785 · one of two readings recorded this
response rate
n = 1442
1374 of 1442 patients (95.28%) receiving the SHL combined with azithromycin and 1186 of 1442 patients (82.25%) receiving azithromycin alone
PMID 34255785 · one of two readings recorded this
mortality in patients with COVID-19, pooled odds ratio, azithromycin versus no azithromycin; abstract only, follow-up horizon not stated
no effect, overall OR: 0.95 (0.79-1.13)
Not recorded as a finding: the paper never states the instrument the node requires
The meta-analysis showed no difference in mortality for those treated with or without azithromycin, in observational studies [OR: 0.90 (0.66-1.24)], RCTs [OR: 0.97 (0.87-1.08)] and also when both types of studies were pooled together [with an overall OR: 0.95 (0.79-1.13)].
PMID 34791330 · one of two readings recorded this
mortality
no effect
also when both types of studies were pooled together [with an overall OR: 0.95 (0.79-1.13)]
PMID 34791330 · one of two readings recorded this
mortality
no effect
in observational studies [OR: 0.90 (0.66-1.24)]
PMID 34791330 · one of two readings recorded this
mortality
no effect
RCTs [OR: 0.97 (0.87-1.08)]
PMID 34791330 · one of two readings recorded this
FEV1 (%) change from baseline, short term (12 weeks or less), pooled pre/post azithromycin
MD: 10.65; 95% CI = 1.63-19.67; P =.02, p = 0.02
Not recorded as a finding: within-arm before/after change, not a between-arm contrast; also a subgroup by duration
Pooled analysis showed a significant difference in FEV1 (%) change values between pre- and posttreatment of azithromycin for short term (MD: 10.65; 95% CI = 1.63–19.67; P =.02), with high heterogeneity (I2 = 86.40%).
PMID 35839027 · one of two readings recorded this
FEV1 (%) compared to baseline, change before vs after azithromycin
no effect
FEV1 (%) compared to baseline (≤12 wk) | HSCT | 2 | 10.28 (–11.01 to 31.57) | 91.13 | 0
PMID 35839027 · one of two readings recorded this
FEV1 (%) compared to baseline, change before vs after azithromycin
no effect
LTx | 4 | 10.93 (–0.57 to 22.43) | 87.56 | 0
PMID 35839027 · one of two readings recorded this
FEV1 (%) compared to baseline, change before vs after azithromycin
increases, p = 0.02
for short term (MD: 10.65; 95% CI = 1.63–19.67; P =.02)
PMID 35839027 · one of two readings recorded this
FEV1 (L) change before versus after azithromycin, mid-term 12-24 weeks, pooled MD
increases, MD 0.22 L (95% CI = 0.05 to 0.39; P =.01; I2 = 41.68%), p = 0.01
Not recorded as a finding: within-arm pre/post change pooled from mostly uncontrolled case series, not a between-arm contrast
The results of the pooled analysis showed an increasing trend in FEV1 (L) between pre– and post–azithromycin treatment, specifically at the mid-term, where the pooled MD in FEV1 (L) was increased by 0.22 L (95% CI = 0.05 to 0.39; P =.01; I2 = 41.68%), manifesting considerable clinical significance.
PMID 35839027 · one of two readings recorded this
FEV1 (L) change before vs after azithromycin
no effect
FEV1 (L) (≤12 wk) | Transplant types | HSCT | 2 | 0.09 (–020 to 0.38) | 0 |.37
PMID 35839027 · one of two readings recorded this
FEV1 (L) change before vs after azithromycin
increases
LTx | 5 | 0.16 (0.08–0.24) | 14.58 |.32
PMID 35839027 · one of two readings recorded this
FEV1 (L) change before vs after azithromycin
no effect, p = 0.65
However, this improvement seemed not to be sustained (MD = 0.11 L; 95% CI = −0.39 to 0.62; P =.65; I2 = 91.00%)
PMID 35839027 · one of two readings recorded this
FEV1 (L) change before vs after azithromycin
increases, p = 0.01
the pooled MD in FEV1 (L) was increased by 0.22 L (95% CI = 0.05 to 0.39; P =.01; I2 = 41.68%)
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
Azithromycin | 3 | 5.80 (–4.49 to 16.09) | 92.57 | 0
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
Azithromycin | 2 | 2.08 (–2.30 to 6.46) | 56.14 | 0
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
FEV1% predicted (12–24 wk) | HSCT | 2 | 1.93 (–1.36 to 5.21) | 0 |.96
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
FEV1% predicted (≤12 wk) | HSCT | 1 | 3.68 (–0.90 to 8.26) | – | –
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
LTx | 3 | 5.80 (–4.49 to 16.09) | 92.57 | 0
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
LTx | 2 | 2.08 (–2.30 to 6.46) | 56.14 | 0
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
FEV1% predicted (12–24 wk) | FAM | 2 | 1.93 (–1.36 to 5.21) | 0 |.96
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
no effect
FEV1% predicted (≤12 wk) | Administration regimen | FAM | 1 | 3.68 (–0.90 to 8.26) | – | –
PMID 35839027 · one of two readings recorded this
FEV1% predicted change before vs after azithromycin
increases, p = 0.01
Pooled analysis showed a significant increase in the predicted FEV1 (%) (MD: 2.99; 95% CI = 0.70–5.27; P =.01; I2 = 14.77%)
PMID 35839027 · one of two readings recorded this
FEV1% predicted, short term (12 weeks or less), pooled pre/post azithromycin
increases, MD: 2.99; 95% CI = 0.70-5.27; P =.01, p = 0.01
Not recorded as a finding: within-arm before/after change, not a between-arm contrast; also a subgroup by duration
Pooled analysis showed a significant increase in the predicted FEV1 (%) (MD: 2.99; 95% CI = 0.70–5.27; P =.01; I2 = 14.77%) between pre– and post–azithromycin short-term treatment.
PMID 35839027 · one of two readings recorded this
survival (risk of death)
decreases
the risk of death was significantly reduced with azithromycin treatment compared with nonazithromycin (HR = 0.26; 95% CI = 0.17–0.40; P =.00)
PMID 35839027 · one of two readings recorded this
carriage of pathogenic organisms (Streptococcus pneumoniae, gut Campylobacter)
decreases
The carriage of pathogenic organisms such as Streptococcus pneumoniae and gut Campylobacter species was reduced
PMID 35970284 · one of two readings recorded this
child mortality after azithromycin mass drug administration (abstract only; follow-up horizon and comparator not stated)
decreases
Not recorded as a finding: no estimate is reported anywhere
Azithromycin MDA reduced child mortality, and quarterly MDA may be most beneficial for reducing child mortality.
PMID 35970284 · one of two readings recorded this
child mortality after azithromycin mass drug administration, pooled across six studies; abstract only
decreases
Not recorded as a finding: the paper never states the instrument the node requires
Azithromycin MDA reduced child mortality, and quarterly MDA may be most beneficial for reducing child mortality.
PMID 35970284 · one of two readings recorded this
child mortality
decreases
Azithromycin MDA reduced child mortality, and quarterly MDA may be most beneficial for reducing child mortality
PMID 35970284 · one of two readings recorded this
diarrhea
decreases
Azithromycin MDA was associated with a lower risk of respiratory tract infections and diarrhea
PMID 35970284 · one of two readings recorded this
fever, vomiting and headache
decreases
Additionally, it was associated with a lower risk of fever, vomiting, and headache
PMID 35970284 · one of two readings recorded this
malaria parasitemia
no effect
No association was observed between azithromycin MDA and malaria parasitemia (rate ratio: 0.71, 95% confidence interval: 0.43-1.15)
PMID 35970284 · one of two readings recorded this
nutritional improvement in children
no effect
Moreover, no association was observed between azithromycin MDA and nutritional improvement in children
PMID 35970284 · one of two readings recorded this
respiratory tract infections
decreases
Azithromycin MDA was associated with a lower risk of respiratory tract infections and diarrhea
PMID 35970284 · one of two readings recorded this
adverse events
no effect, p = 0.07
adverse events (OR = 0.90; 95% CI 0.80–1.01; P = 0.07
PMID 36221151 · one of two readings recorded this
FEV1
no effect, p = 0.39
no obvious influence on FEV1 (SMD = 0.29; 95% CI − 0.37 to 0.96; P = 0.39
PMID 36221151 · one of two readings recorded this
free of exacerbation
increases, p = 0.001
significantly improved free of exacerbation (OR = 3.66; 95% CI 1.69–7.93; P = 0.001)
PMID 36221151 · one of two readings recorded this
nausea or vomiting
no effect, p = 0.5
nausea or vomiting (OR = 1.29; 95% CI 0.61–2.69; P = 0.50
PMID 36221151 · one of two readings recorded this
number of pulmonary exacerbations
decreases, p = 0.00001
substantially reduce the number of pulmonary exacerbations (SMD = − 0.87; 95% CI − 1.21 to − 0.54; P < 0.00001
PMID 36221151 · one of two readings recorded this
pulmonary exacerbations
decreases, p = 0.001
reduced pulmonary exacerbations (OR = 0.27; 95% CI 0.13–0.59; P = 0.001)
PMID 36221151 · one of two readings recorded this
score on St George’s respiratory questionnaire
no effect, p = 0.69
score on St George’s respiratory questionnaire (SMD = − 1.02; 95% CI − 6.11 to 4.06; P = 0.69
PMID 36221151 · one of two readings recorded this
azithromycin resistance, between-study heterogeneity
p = 0.01
(I2=98.76%; P=0.01) was observed between
PMID 36568835 · one of two readings recorded this
azithromycin resistance, countries with >5% resistant specimens
n = 51
Among 51 countries reporting resistance data for azithromycin, 22
PMID 36568835 · one of two readings recorded this
azithromycin resistance rate, difference between continents
p = 0.01
between different continents (P <0.01)
PMID 36568835 · one of two readings recorded this
azithromycin resistance rate, method used for AST and interpretation of resistance
no effect, p = 0.36
and the interpretation of resistance (P=0.36)
PMID 36568835 · one of two readings recorded this
azithromycin resistance rate, South America versus Africa
Africa (9.2% vs. 5.3%)
PMID 36568835 · one of two readings recorded this
azithromycin resistance rate, South America versus Asia
higher in South America than Asia (9.2% vs. 6.3%)
PMID 36568835 · one of two readings recorded this
azithromycin resistance rate, South America versus Europe
Europe (9.2% vs. 5.8%)
PMID 36568835 · one of two readings recorded this
azithromycin resistance rate, South America versus North America
North America (9.2% vs. 2.1%,)
PMID 36568835 · one of two readings recorded this
azithromycin resistance, worldwide pooled rate (WPR)
n = 165172
NG isolates; the WPR was 6% (95% CI 5%-7%) with substantial heterogeneity
PMID 36568835 · one of two readings recorded this
azithromycin resistance, WPR
1988-2013 (WPR 2.31%; 95% CI 1.40%-3.40%)
PMID 36568835 · one of two readings recorded this
azithromycin resistance, WPR
2014-2018 (WPR 6.85%; 95% CI
PMID 36568835 · one of two readings recorded this
azithromycin resistance, WPR
increases
2019-2021 (WPR 7.25%; 95% CI 5.62%-9.06%)
PMID 36568835 · one of two readings recorded this
erythromycin resistance, between-study heterogeneity
p = 0.01
heterogeneity (I2=98.69%, P< 0.01) was observed
PMID 36568835 · one of two readings recorded this
erythromycin resistance prevalence
prevalence of erythromycin resistance notably increased from 17.16% (95% CI
PMID 36568835 · one of two readings recorded this
erythromycin resistance prevalence
increases, n = 1569
6.08-32.12) of 18 strains 1988-2013 reaching 72% (95% CI 50.61-87.93) of 1,569
PMID 36568835 · one of two readings recorded this
erythromycin resistance rate, difference between continents
no effect, p = 0.83
continents (P=0.83)
PMID 36568835 · one of two readings recorded this
erythromycin resistance rate, method used for AST
no effect, p = 0.08
method used for AST (P=0.08)
PMID 36568835 · one of two readings recorded this
erythromycin resistance, worldwide pooled rate (WPR)
n = 13161
13,161 NG isolates; the WPR was 21% (95% CI 13%-29%) with substantial
PMID 36568835 · one of two readings recorded this
publication bias (Egger's test)
no effect, p = 0.297
Egger’s test showed no obvious publication bias in the rate of azithromycin treatment efficiency (p = 0.297)
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 50
Škerk 2000 | Croatia | 2000 | 44 | 50 | 0.5 g | qd | po | 6d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 30
Skerk 2000 | Croatia | 2000 | 17 | 30 | 0.5 g | qd | po | 6d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 21
Fatih Sendag 2000 | Turkey | 2000 | 15 | 21 | 1 g | once | po | 1d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 30
Skerk 2000 | Croatia | 2000 | 28 | 30 | 1 g | Once | po | 1d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 14
Steingrimssoir Olafnr 1990 | USA | 1990 | 11 | 14 | 1 g | once | po | 1d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 90
Wen-E Liu 2013 | China | 2013 | 13 | 90 | 1 g | qd | po | 7d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 5
Steingrimssoir Olafnr 1990 | USA | 1990 | 5 | 5 | 500 mg d1, 250 mg d2–3 | qd | po | 3d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 98
Wen-E Liu 2013 | China | 2013 | 20 | 98 | Chinese Traditional Medicine | 10 g | tid | po | 14d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 30
Skerk 2000 | Croatia | 2000 | 28 | 30 | Doxycycline | 100 mg | bid | po | 14d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 22
Fatih Sendag 2000 | Turkey | 2000 | 17 | 22 | Doxycycline | 100 mg | bid | po | 7d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 64
Škerk 2000 | Croatia | 2000 | 47 | 64 | Doxycycline | 100 mg | bid | po | 7d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 30
Skerk 2000 | Croatia | 2000 | 28 | 30 | Doxycycline | 100 mg | bid | po | 7d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 12
Steingrimssoir Olafnr 1990 | USA | 1990 | 9 | 12 | Doxycycline | bid | po | 1d
PMID 36927441 · one of two readings recorded this
treatment response cases
n = 16
Steingrimssoir Olafnr 1990 | USA | 1990 | 12 | 16 | Doxycycline | bid | po | 7d
PMID 36927441 · one of two readings recorded this
treatment response (cure) of Ureaplasma urealyticum infection
no effect, n = 512
The fixed effect of RR was 1.03 [0.94, 1.12], while the random effect of RR was 0.98 [0.80, 1.20]
PMID 36927441 · one of two readings recorded this
treatment response (cure) of Ureaplasma urealyticum infection
no effect, n = 512
The fixed effect of RR was 1.03 [0.94, 1.12], while the random effect of RR was 0.98 [0.80, 1.20]
PMID 36927441 · one of two readings recorded this
treatment response (cure) of Ureaplasma urealyticum infection
no effect
The fixed effect of RR in subgroup of a single dose of 1 g was 0.99 [0.88, 1.12] and in subgroup of 0.5 g QD for 7 days was 1.02 [0.87, 1.20]
PMID 36927441 · one of two readings recorded this
treatment response (cure) of Ureaplasma urealyticum infection
no effect
The fixed effect of RR in subgroup of a single dose of 1 g was 0.99 [0.88, 1.12] and in subgroup of 0.5 g QD for 7 days was 1.02 [0.87, 1.20]
PMID 36927441 · one of two readings recorded this
treatment response (cure) of Ureaplasma urealyticum infection
no effect
The fixed effect of RR was 1.04 [0.95, 1.13]
PMID 36927441 · one of two readings recorded this
treatment response (microbiological cure) of Ureaplasma urealyticum infection in the female reproductive tract, pooled risk ratio
no effect
Not recorded as a finding: the comparison was against another active treatment
Compared to other antibiotics, azithromycin has a comparable therapeutic effect on Ureaplasma urealyticum infection.
PMID 36927441 · one of two readings recorded this
treatment response (mycoplasma cure) of Ureaplasma urealyticum infection in the female reproductive tract, pooled risk ratio
no effect
Not recorded as a finding: the comparison was against another active treatment
Compared to other antibiotics, azithromycin has a comparable therapeutic effect on Ureaplasma urealyticum infection.
PMID 36927441 · one of two readings recorded this
induction of arrhythmia
no effect, n = 9723
induction of arrhythmia [(n= 9,723 patients) OR= 1.21 (95% CI: 0.63-2.32)
PMID 36996755 · one of two readings recorded this
mortality
no effect, n = 27204
statistically insignificant reduction in mortality [(n= 27,204 patients) OR= 0.77 (95% CI: 0.51-1.16)
PMID 36996755 · one of two readings recorded this
QTc prolongation
no effect, n = 6534
QTc prolongation (a surrogate for torsadogenic effect) [(n= 6,534 patients) OR= 0.62 (95% CI: 0.23-1.73)
PMID 36996755 · one of two readings recorded this
requirement of mechanical ventilation
no effect, n = 14908
requirement of mechanical ventilation [(n= 14,908 patients) OR= 1.4 (95% CI: 0.58-3.35)
PMID 36996755 · one of two readings recorded this
adverse reaction incidence, in children with respiratory disease treated with azithromycin
decreases, OR = 0.42, 95% CI 0.12-0.72
Not recorded as a finding: the comparison was against another active treatment
The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).
PMID 38050289 · one of two readings recorded this
adverse reaction incidence, intravenous administration subgroup
decreases, OR = 0.57, 95% CI 0.12-0.84
In the subgroup of intravenous administration, AZM had a lower the incidence of adverse reactions (OR = 0.57, 95% CI 0.12-0.84, P = .003).
PMID 38050289 · one of two readings recorded this
adverse reaction incidence, oral administration subgroup
decreases, OR = 0.45, 95% CI 0.13-0.69
In the subgroup of oral administration, AZM had a lower the incidence of adverse reactions (OR = 0.45, 95% CI 0.13-0.69 P < .001).
PMID 38050289 · one of two readings recorded this
adverse reaction incidence, sequential therapy subgroup
decreases, OR = 0.29, 95% CI 0.09-0.60
In the subgroup of sequential therapy, AZM had a lower incidence of adverse reactions in sequential therapy (OR = 0.29, 95% CI 0.09-0.60, P < .001).
PMID 38050289 · one of two readings recorded this
incidence of adverse reactions after azithromycin (AZM) treatment in pediatric respiratory disease RCTs, vs a control group whose composition the abstract never states
decreases, OR = 0.42, 95% CI 0.12-0.72, P < .001
Not recorded as a finding: another reason, stated per paper
The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).
PMID 38050289 · one of two readings recorded this
incidence of adverse reactions after azithromycin treatment, pediatric respiratory disease RCTs
decreases, OR = 0.42, 95% CI 0.12-0.72, P < .001
The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).
PMID 38050289 · one of two readings recorded this
incidence of adverse reactions, intravenous administration subgroup
decreases, OR = 0.57, 95% CI 0.12-0.84, P = .003, p = 0.003
In the subgroup of intravenous administration, AZM had a lower the incidence of adverse reactions (OR = 0.57, 95% CI 0.12-0.84, P = .003).
PMID 38050289 · one of two readings recorded this
incidence of adverse reactions, oral administration subgroup
decreases, OR = 0.45, 95% CI 0.13-0.69, P < .001
In the subgroup of oral administration, AZM had a lower the incidence of adverse reactions (OR = 0.45, 95% CI 0.13-0.69 P < .001).
PMID 38050289 · one of two readings recorded this
incidence of adverse reactions, sequential therapy subgroup
decreases, OR = 0.29, 95% CI 0.09-0.60, P < .001
In the subgroup of sequential therapy, AZM had a lower incidence of adverse reactions in sequential therapy (OR = 0.29, 95% CI 0.09-0.60, P < .001).
PMID 38050289 · one of two readings recorded this
overall adverse reaction incidence
decreases, OR = 0.42, 95% CI 0.12-0.72
The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).
PMID 38050289 · one of two readings recorded this
clinically diagnosed asthma
no effect, RR 0.94 (CI 0.29-3.10), n = 227
Not recorded as a finding: no_outcome_node: no node for asthma diagnosis incidence
Pooled estimate for asthma did not show any difference between the groups (0.94, CI 0.29–3.10; Supplementary Fig. 3).
PMID 38066246 · one of two readings recorded this
gastrointestinal adverse events
no effect, RD 2.0% (CI -1.0% to 5.0%), n = 268
Two studies (268 children) focused on gastrointestinal adverse events and did not find significant difference between the groups (RD 2.0%, CI –1.0% to 5.0%; Supplementary Fig. 4).
PMID 38066246 · both readings recorded this
hospital readmission (pooled across follow-up timepoints)
no effect, risk ratio 1.14 (CI 0.82–1.60)
Not recorded as a finding: no outcome node in the supplied list covers hospital readmission rate
When all of the previous timepoints were pooled together the risk ratio for readmission to hospital was 1.14 (CI 0.82–1.60; Supplementary Fig. 1).
PMID 38066246 · one of two readings recorded this
Hospital readmission (pooled timepoints)
no effect, RR 1.14 (CI 0.82-1.60)
When all of the previous timepoints were pooled together the risk ratio for readmission to hospital was 1.14 (CI 0.82–1.60; Supplementary Fig. 1).
PMID 38066246 · one of two readings recorded this
hospital readmission
RR 1.14 (CI 0.82-1.60), n = 585
Not recorded as a finding: no_outcome_node: no node for hospital readmission rate
When all of the previous timepoints were pooled together the risk ratio for readmission to hospital was 1.14 (CI 0.82–1.60; Supplementary Fig. 1).
PMID 38066246 · one of two readings recorded this
need for paediatric intensive care unit (PICU) admission
no effect, pooled RD 0.0%, CI –2.0% to 2.0%, n = 446
Not recorded as a finding: no outcome node in the supplied list covers PICU admission (distinct from ICU length-of-stay)
Four studies (446 children) analyzed the need for PICU admission and one child in the azithromycin group (0.5%) and four children in the control group (1.8%) were admitted to PICU (pooled RD 0.0%, CI –2.0% to 2.0%; Fig. 3).
PMID 38066246 · one of two readings recorded this
Need for PICU admission
no effect, pooled RD 0.0% (CI -2.0% to 2.0%), n = 446
Four studies (446 children) analyzed the need for PICU admission and one child in the azithromycin group (0.5%) and four children in the control group (1.8%) were admitted to PICU (pooled RD 0.0%, CI –2.0% to 2.0%; Fig. 3).
PMID 38066246 · one of two readings recorded this
overall length of hospitalization
decreases, n = 325
Three studies with 325 children analyzed the overall length of hospitalization period, and the mean difference was -0.27 days (CI –0.47 to –0.07 days; Fig. 4) favoring azithromycin group.
PMID 38066246 · both readings recorded this
recurrence of wheezing episode
RR 0.84 (CI 0.45-1.56), n = 297
Not recorded as a finding: no_outcome_node: no node for wheezing recurrence
After pooling of these studies, the risk ratio for at least one recurrence of wheezing episode was 0.84 (CI 0.45–1.56; Supplementary Fig. 2).
PMID 38066246 · one of two readings recorded this
recurrence of wheezing (pooled across follow-up timepoints)
no effect, risk ratio 0.84 (CI 0.45–1.56)
Not recorded as a finding: no outcome node in the supplied list covers recurrence of wheezing
After pooling of these studies, the risk ratio for at least one recurrence of wheezing episode was 0.84 (CI 0.45–1.56; Supplementary Fig. 2).
PMID 38066246 · one of two readings recorded this
Recurrence of wheezing (pooled timepoints)
no effect, RR 0.84 (CI 0.45-1.56)
After pooling of these studies, the risk ratio for at least one recurrence of wheezing episode was 0.84 (CI 0.45–1.56; Supplementary Fig. 2).
PMID 38066246 · one of two readings recorded this
clinical failure, mortality, treatment-related adverse effects
no effect
Additionally, there was no difference between the two arms concerning clinical failure, mortality and treatment-related adverse effects.
PMID 38110855 · one of two readings recorded this
clinical failure rate, scrub typhus, doxycycline vs azithromycin
no effect
Additionally, there was no difference between the two arms concerning clinical failure, mortality and treatment-related adverse effects.
PMID 38110855 · one of two readings recorded this
mortality, scrub typhus, doxycycline vs azithromycin
no effect
Additionally, there was no difference between the two arms concerning clinical failure, mortality and treatment-related adverse effects.
PMID 38110855 · one of two readings recorded this